Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer

KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma

Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma

CB-839 in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer

ASCO GU 2019 renal highlights

BGICC 2019

Combined ibrutinib and venetoclax in patients with treatment-naïve high-risk CLL

Phase II trial of nivolumab combined with ibrutinib for patients with Richter transformation

Cytotoxic T lymphocyte cell therapy for post-transplant lymphoproliferative disorder in the central nervous system

Blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-NHL

Gilteritinib combined with induction and consolidation chemotherapy in newly diagnosed AML patients

ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients with T-Cell lymphomas